Treatment success and mortality among people with multi-drug resistant and rifampicin resistant-tuberculosis on bedaquiline-based regimen at three referral hospitals in Uganda: A retrospective analysis
Lodiong Jackson Dumo Lodiong, Jonathan Izudi, Boniface Amanee Elias Lumori · 2024
Read Treatment success and mortality among people with multi-drug resistant and rifampicin resistant-tuberculosis on bedaquiline-based regimen at three referral hospitals in Uganda: A retrospective analysis by Lodiong Jackson Dumo Lodiong, Jonathan Izudi, Boniface Amanee Elias Lumori (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11626816.txt.
Description
Lodiong and co-authors review records in 2024 for Ugandans treated for drug-resistant tuberculosis with a newer drug at the core. The drug, bedaquiline, entered the national regimen in 2020, yet outcomes under it had not been closely studied. Records came from three referral hospitals for 2020 and 2021.
Seventy-one patients aged fifteen or more were tracked to cure, completion, or failure. Success was counted as cure or finished course. A risk model then weighed which traits traveled with success, with tight math for a small group. Early real-world returns matter for resistant TB: each success is a long, costly course finished, and each failure risks spreading a harder germ in their care.
Catalog record
| CREATOR | Lodiong Jackson Dumo Lodiong, Jonathan Izudi, Boniface Amanee Elias Lumori |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |